There are currently 26 clinical trials in Miami Springs, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Ocean Blue Medical Research Center, Inc., South Florida Research Phase I-IV, Inc. and Galiz Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0015, Miami Springs, Florida
Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
07/18/2025
Locations: Ocean Blue Medical Research Center, Inc /ID# 217286, Miami Springs, Florida
Conditions: Endometriosis
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/14/2025
Locations: South Florida Research Ph I-IV /ID# 240778, Miami Springs, Florida
Conditions: Depression, Bipolar I Disorder
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Recruiting
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/14/2025
Locations: Local Institution - 0069, Miami Springs, Florida
Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
07/14/2025
Locations: Ocean Blue Medical Research Center Inc, Miami Springs, Florida +1 locations
Conditions: Psychosis Associated With Alzheimer's Disease
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator site, Miami Springs, Florida
Conditions: Major Depressive Disorder
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Miami Springs, Florida
Conditions: Major Depressive Disorder
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
07/09/2025
Locations: South Florida Research, Miami Springs, Florida
Conditions: Proteinuric Kidney Disease
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: South Florida Research Phase I-IV, Inc, Miami Springs, Florida
Conditions: Pediatric Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: South Florida Research Phase I-IV, Inc, Miami Springs, Florida
Conditions: Acute Treatment of Migraine
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Recruiting
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/07/2025
Locations: Clinical Site, Miami Springs, Florida
Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2025
Locations: Research Site, Miami Springs, Florida
Conditions: Asthma